These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15338383)

  • 1. Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
    Yokosuka O
    J Gastroenterol; 2004 Aug; 39(8):813-4. PubMed ID: 15338383
    [No Abstract]   [Full Text] [Related]  

  • 2. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
    Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
    Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
    Yang DH; Xie YJ; Liang WF; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):496-7. PubMed ID: 15329216
    [No Abstract]   [Full Text] [Related]  

  • 4. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of lamivudine and interferon-alpha combination therapy on chronic hepatitis B].
    Tang Y; Chen G; Zheng R
    Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):89. PubMed ID: 11983118
    [No Abstract]   [Full Text] [Related]  

  • 8. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.
    Nikolaidis NL; Giouleme OI; Tziomalos KA; Saveriadis AS; Grammatikos N; Doukelis P; Voutsas AD; Vassiliadis T; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis NP
    J Gastroenterol Hepatol; 2005 Nov; 20(11):1721-5. PubMed ID: 16246192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
    Horiike N; Duong TN; Michitaka K; Joko K; Hiasa Y; Konishi I; Yano M; Onji M
    J Med Virol; 2007 Jul; 79(7):911-8. PubMed ID: 17516520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
    Chan HL; Wong VW; Hui AY; Tsang SW; Chan JL; Chan HY; Wong GL; Sung JJ
    Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
    Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
    J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha].
    Pariente A; Tachet A; Poveda JD
    Gastroenterol Clin Biol; 2002 Nov; 26(11):1059-60. PubMed ID: 12483147
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
    J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lamivudine treatment for hepatitis B].
    Lamivudine Clincal Practice Group
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.